Thursday, June 24, 2010
16:00-19:00 Registration
FRIDAY, JUNE 25, 2010
09:00 – 09:10 Welcome
Josep M. Llovet, Spain/ USA and Jorge Marrero, USA
09:10-11:00 Symposium 1: Epidemiology and Surveillance
Chairs: Josep M. Llovet, Spain/ USA and Morris Sherman, Canada
09:10 Cost Efficacy Analysis of surveillance for Hepatocellular Carcinoma
Morris Sherman, Canada
09.35 HCC in developing countries
Flair Carrilho, Brazil
10:05 Assessment of early HCC detection in Western countries
Alejandro Forner, Spain
10.30 Prevention of HCC
Adrian di Bisceglie, USA
11.00-11:30 Coffee Break and Poster Viewing
11:30-13:30 Symposium 2: Signaling and Driver Oncogenes in HCC
Chairs: Jessica Zucman-Rossi, France, Yujin Hoshida, USA
11.30 Linking fibrosis with cancer risk: molecular perspective
Yujin Hoshida, USA
12:00 Critical appraisal of signaling pathways in HCC
Augusto Villanueva, Spain
12:30 Angiogenesis in hepatocarcinogenesis
David Semela, Switzerland
13:00 Genomics in HCC: tumor vs. microenvironment, where are the targets?
Snorri Thorgeirsson, USA
13:30-14:30 Lunch Break and Poster Viewing
14:30-15:15 Keynote Lecture: Milestones in the management of HCC
Massimo Colombo, Italy
15:15-17:15 Symposium 3: Diagnosis of early HCC: pathology and radiology
Chairs: Jorge Marrero, USA, Tania Roskams, Belgium
15.15 International Consensus Group: Pathologic diagnosis
Tania Roskams, Belgium
15:45 Molecular diagnosis of HCC
Valérie Paradis, France
16.15 Review of radiologic diagnosis
Luigi Bolondi, Italy
16:45 Integrative clinical and molecular approach for diagnosis
Jorge Marrero, USA
17:15-17:45 Coffee Break and Poster Viewing
17:45-19:45 Symposium 4: Clinical and Molecular Classification of HCC
Chairs: Jordi Bruix, Spain and Masatoshi Kudo, Japan
17.45 Clinical Staging systems and prognosis in the West
Jordi Bruix, Spain
18.15 Clinical classification in Asia
Masatoshi Kudo, Japan
18.45 Role of TNM in HCC stratification
Ronnie Poon, China
19.15 Molecular classification and biomarkers in HCC
Jessica Zucman-Rossi, France
19:45 Welcome Reception
Saturday, June 26, 2010
09:00-11:00 Symposium 5: Novel concepts in surgery for hepatocellular carcinoma
Chairs: Vincenzo Mazzaferro, Italy and Myron Schwartz, USA
09.00 Should we expand current criteria for resection/ OLT?
Myron Schwartz, USA
09:30 Outcome after OLT: Metroticket proposal
Vincenzo Mazzaferro, Italy
10:00 Critical appraisal of LDLT in HCC after 20 years
Pierre Clavien, Switzerland
10:30 How to handle waiting times for OLT: MELD and beyond
Fabio Piscaglia, Italy
11:00-11:30 Coffee Break and Poster Viewing
11:30-13:30 Symposium 6: Loco-regional approaches for hepatocellular carcinoma
Chairs: Masao Omata, Japan and Flair Carrilho, Brazil
11.30 HCC: Future of image-guided radiofrequency ablation in 5-10 years
Riccardo Lencioni, Italy
12:00 Novel devices for ablation, HIFU and beyond
Masao Omata, Japan
12:30 Who benefits from chemoembolization
Michel Beaugrand, France
13:00 Can internal radiation compete with TACE?
Laura Kulik, USA
13:30-14:30 Lunch Break and Poster Viewing
14:30-16:30 Symposium 7: Current systemic therapies in HCC
Chairs: Josep M. Llovet, Spain/ USA and Ann-Li Cheng, Taiwan
14:30 Sorafenib: Implications in management and trial design
Josep M. Llovet, Spain / USA
15:00 Who benefits most from sorafenib treatment?
Ann-Li Cheng, Taiwan
15.30 Active trials: First line and second line
Eric Raymond, France
16:00 Are there still opportunities for chemotherapy in HCC?
Tim Meyer, UK
16:30-17:00 Coffee Break and Poster Viewing
17:00-19:00 Symposium 8: Novel Molecular therapies and Future Trials
Chairs: Peter Galle, Germany, Masao Omata, Japan
17.00 Overview of pre-clinical data with novel drugs in HCC
Peter Galle, Germany
17.30 Novel anti-proliferative vs. Anti-angiogenic drugs
Richard Finn, USA
18.00 Is there a rationale for immunotherapy of HCC?
Tim Greten, USA
18.30 Adjuvant therapies after resection / local ablation
Masao Omata, Japan
19:00 Closing Remarks